Worth reading
86Important
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
691
Millions of yen (operating profit)Wording
Definitive
How definitive the wording is.Contents of this document
Earnings presentation materialsFull year ended September 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,990 million+52.5%
Operating profit¥691 million+358.3%
Ordinary income¥684 million+349.1%
Net income¥752 million+1,606.4%
Selling, general and administrative expenses¥1,450 million
Operating profit margin23.1% (+15.4 percentage points year on year)
Results for the three months of the current quarter
Net Sales
¥950 million
Gross profit
¥666 million
Selling, general and administrative expenses
¥390 million
Operating profit
¥275 million
Ordinary income
¥274 million
Net income
¥359 million
Operating profit margin29.0%
Full-year earnings forecast
Fiscal year ending September 2027
Net Sales
¥4,151 million
Operating profit
¥880 million
Ordinary income
¥870 million
Net income
¥521 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。Fiscal year ended September 2026 actual results versus forecasts: revenue was +27.5% versus the initial forecast, +19.6% versus the first revised forecast and +8.7% versus the second revised forecast. Operating profit was +127.6%, +72.9% and +23.5%, respectively. Ordinary profit was +132.8%, +75.5% and +24.4%, respectively. Net income was +308.9%, +200.9% and +83.5%, respectively.
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Results exceeded the forecast issued after 2 upward revisions.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Fiscal Year Ending September 2027 Sales Plan
Medical Support business¥1,020 million
D2C business¥-204 million
Other・Overseas Business¥347 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
PDF-FD・CPCNumber of clinics listed on PDF-FD, utilization rate of contracted clinics, and number of CPC orders
Supernatant・OEMShipment volume and unit price, shipment volume of new products, and revenue outside the SBC Group
Aesthetic Medical CosmeticsNumber of television-shopping broadcasts and units sold per day
Overseas BusinessMonthly sales of core products, number of clinics transacting outside the SBC Group, and number of new projects adopted
New initiatives
- Deepening collaboration with SBC Medical Group
- Launch of CPC (contracted cell processing)
- Launch of new iPS conditioned-medium and hair follicle stem cell extract products
- Expansion of sales channels outside the SBC Group
- Expansion of products handled from overseas and new products
Key KPIsA metric the company considers important as a management benchmark.
- Cumulative number of PDF-FD processing orders received23,841 casesYear on year against the same period last year+53.0%
- Cumulative number of PDF-FD affiliated clinics883 clinicsYear on year against the same period last year+28.9%
- Average outsourced processing orders per day29.4 casesYear on year against the same period last year+28.9%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Contracted/order unit price, number of contracted/orders, and average number of contracted processing orders per day are disclosed, but the actual unit price is Not disclosedSegment results
Medical Support business
Net Sales
¥2,012 million
Year on year against the same period last year+101.4%
Fourth-quarter segment profit
¥248 million
4Q Profit_yoy_pct25.5
D2C business
Net Sales
¥697 million
Year on year against the same period last year-26.8%
Other・Overseas Business
Net Sales
¥280 million
Fourth-quarter segment profit
¥102 million
Financial targets
Equity ratio
Actual results68.7%
vs. End of Previous Fiscal Year+3.6 percentage points
Number of stores and locations
Number of SBC Group clinics: 284 locations in Japan and overseas (as of the end of March 2026). Number of company-operated stores and openings/closures: Not disclosed| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Full year ended September 2026 |
| Net Sales | ¥2,990 million (YoY +52.5%) |
| Operating profit | ¥691 million (YoY +358.3%) |
| Ordinary income | ¥684 million (YoY +349.1%) |
| Net income | ¥752 million (YoY +1,606.4%) |
| Operating profit margin | 23.1% (+15.4 percentage points year on year) |
| Selling, general and administrative expenses | ¥1,450 million |
| Results for the three months of the current quarter | Net Sales ¥950 million / Gross profit ¥666 million / Selling, general and administrative expenses ¥390 million / Operating profit ¥275 million / Ordinary income ¥274 million / Net income ¥359 million / Operating profit margin 29.0% |
| Full-year earnings forecast | Fiscal year ending September 2027 Net Sales ¥4,151 million / Operating profit ¥880 million / Ordinary income ¥870 million / Net income ¥521 million |
| Progress against full-year forecast | Fiscal year ended September 2026 actual results versus forecasts: revenue was +27.5% versus the initial forecast, +19.6% versus the first revised forecast and +8.7% versus the second revised forecast. Operating profit was +127.6%, +72.9% and +23.5%, respectively. Ordinary profit was +132.8%, +75.5% and +24.4%, respectively. Net income was +308.9%, +200.9% and +83.5%, respectively. |
| Self-assessment against the plan | Results exceeded the forecast issued after 2 upward revisions. |
| Segment results | Medical Support business Net Sales ¥2,012 million / yoy_pct 101.4 / Fourth-quarter segment profit ¥248 million / 4Q Profit_yoy_pct 25.5 / D2C business Net Sales ¥697 million / yoy_pct -26.8 / Fourth-quarter segment profit Not disclosed / Other・Overseas Business Net Sales ¥280 million / yoy_pct Not disclosed / Fourth-quarter segment profit ¥102 million |
| Breakdown of Factors Affecting the Change | Fiscal Year Ending September 2027 Sales Plan Medical Support business ¥1,020 million / D2C business ¥-204 million / Other・Overseas Business ¥347 million |
| Key KPIs | Indicator name Cumulative number of PDF-FD processing orders received / Value 23,841 cases / Year on year against the same period last year 53 cases, Indicator name Cumulative number of PDF-FD affiliated clinics / Value 883 clinics / Year on year against the same period last year 28.9 clinics, Indicator name Average outsourced processing orders per day / Value 29.4 cases / Year on year against the same period last year 28.9 cases |
| Unit price and quantity metrics | Contracted/order unit price, number of contracted/orders, and average number of contracted processing orders per day are disclosed, but the actual unit price is Not disclosed |
| Number of stores and locations | Number of SBC Group clinics: 284 locations in Japan and overseas (as of the end of March 2026). Number of company-operated stores and openings/closures: Not disclosed |
| Assumptions Underlying the Business Outlook | PDF-FD・CPC Number of clinics listed on PDF-FD, utilization rate of contracted clinics, and number of CPC orders / Supernatant・OEM Shipment volume and unit price, shipment volume of new products, and revenue outside the SBC Group / Aesthetic Medical Cosmetics Number of television-shopping broadcasts and units sold per day / Overseas Business Monthly sales of core products, number of clinics transacting outside the SBC Group, and number of new projects adopted |
| Financial targets | Equity ratio Actual results 68.7% / vs. End of Previous Fiscal Year +3.6 percentage points / Other Not disclosed |
| New initiatives | Deepening collaboration with SBC Medical Group, Launch of CPC (contracted cell processing), Launch of new iPS conditioned-medium and hair follicle stem cell extract products, Expansion of sales channels outside the SBC Group, Expansion of products handled from overseas and new products |
Items this document does not state (11)
Gross Profit MarginNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the collaboration with SBC Medical Group announced in the first quarter was incorporated from the second quarter, and its contribution to earnings emerged from the second half. The Medical Support business in particular grew strongly.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.